Efficacy of cross‐line anti‐programmed death 1/programmed cell death‐ligand 1 antibody in the treatment of advanced nonsmall cell lung cancer: A retrospective study

Documenti analoghi

• Seasonal influences on the efficacy of anti–programmed cell death (ligand) 1 inhibitors in lung cancer
  di: Hyunsoon Cho, et al.
  Pubblicazione: (2024)
• Cemiplimab monotherapy as first‐line treatment of patients with brain metastases from advanced non–small cell lung cancer with programmed cell death‐ligand 1 ≥50%
  di: Saadettin Kilickap, et al.
  Pubblicazione: (2025)
• Establishing a new human lung squamous cell carcinoma cell line, OMUL‐1, expressing insulin‐like growth factor 1 receptor and programmed cell death ligand 1
  di: Hiroaki Nagamine, et al.
  Pubblicazione: (2024)
• Nanoscale engagement of programmed death ligand 1 ( PD ‐ L1 ) in membrane lipid raft domains of cancer cells
  di: Simone Civita, et al.
  Pubblicazione: (2025)
• Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade
  di: Eric J. Miller, et al.
  Pubblicazione: (2024)